Conleth G. Murphy

2.1k citations
55 papers · 1.5k · 2 hit papers · h-index 19

Impact in

  • Oncology top 2%
    • HER2/EGFR in Cancer Research
    • PARP inhibition in cancer therapy
    • Lung Cancer Research Studies
    • Cancer Treatment and Pharmacology
    • Ovarian cancer diagnosis and treatment

Papers in

    • HER2/EGFR in Cancer Research 16
    • Cancer Treatment and Pharmacology 9
    • PARP inhibition in cancer therapy 7
    • Advanced Breast Cancer Therapies 8
    • Lung Cancer Treatments and Mutations 6

Conleth G. Murphy

53 papers receiving 1.4k citations

Conleth G. Murphy's Hit Papers

Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study 2023 · 220 citations
2200+1+3Years since publication50100150200

Peers

Conleth G. Murphy
Comparison fields: 5 of 91
  • Oncology 1.0k
  • Reproductive Medicine 282
  • Cancer Research 218
  • Genetics 146
  • Pulmonary and Respiratory Medicine 430
Replace Mayu Yunokawa with:
Mayu Yunokawa Japan
Thomas Makatsoris Greece
Jean‐François Martini United States
Henrik Roed Denmark
Antonio Febbraro Italy
Linnea Chap United States
Akihiko Shimomura Japan
Véronique D’Hondt France
Franco Caramia Australia
Josep Garcia Switzerland
Conleth G. Murphy relative to Mayu Yunokawa Japan Mayu Yunokawa's profile →
Citations per field
00.5×
Mayu Yunokawa · 1×
Citations per year

Countries citing papers authored by Conleth G. Murphy

Since Specialization
Citations

This map shows the geographic impact of Conleth G. Murphy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Conleth G. Murphy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Conleth G. Murphy more than expected).

Fields of papers citing papers by Conleth G. Murphy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Conleth G. Murphy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Conleth G. Murphy. The network helps show where Conleth G. Murphy may publish in the future.

Co-authors

The 25 scholars most cited alongside Conleth G. Murphy, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Conleth G. Murphy Line = papers co-authored together Conleth G. Murphy links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 55 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study
Hit paper breakdown →
2023220
2
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I
Hit paper breakdown →
2021186
3 2014132
4 2015108
5 201694
6 201175
7 201256
8 200952
9 201050
10 201940
11 201936
12 201535
13 201035
14 201934
15 201232
16
HER2-positive breast cancer: beyond trastuzumab.
201031
17 201630
18 201130
19 201422
20 202218

About Conleth G. Murphy

Conleth G. Murphy is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Reproductive Medicine, Cancer Research and Molecular Biology, having authored 55 papers that have together received 1.5k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (16 papers), Ovarian cancer diagnosis and treatment (13 papers), Cancer Treatment and Pharmacology (9 papers), Breast Cancer Treatment Studies (8 papers), Advanced Breast Cancer Therapies (8 papers), PARP inhibition in cancer therapy (7 papers), Lung Cancer Treatments and Mutations (6 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). The work is most often cited by research in Oncology (1.0k citations), Reproductive Medicine (282 citations), Cancer Research (218 citations), Genetics (146 citations) and Pulmonary and Respiratory Medicine (430 citations). Conleth G. Murphy has collaborated with scholars based in Ireland, United States and Spain. Frequent co-authors include Maura N. Dickler, Andrew D. Seidman, Patrick G. Morris, Mary Ellen Moynahan, Shanu Modi, Domenica Lorusso, Ana Oaknin, Jason Konner, Nicoletta Colombo and Monica Fornier. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Gynecologic Oncology, International Journal of Gynecological Cancer and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact